Clinical Trial

Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 22, 2020 (before its estimated June 2022 completion). Its status may not reflect the trial's current state.
Summary
This study is a one-arm, open, phase II clinical study, and the study subjects are locally advanced and inflammatoryPatients with sexual or early HER2-positive breast cancer entered the trial period after signing informed consentTo evaluate trastuzumab combined with pyrrolitinib and chemotherapy regimen (TCbH+Py) for HER2 positive breastPathologic complete response rate (pCR) for adenocarcinoma.
Trial Details
NCT Number NCT04481932
Lead Sponsor Peking University
Conditions HER2-positive Breast Cancer
Enrollment 104 participants
Start Date 2020-07
Primary Completion 2022-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2020-07-22